Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8FF0

Structure of BTK kinase domain with the second-generation inhibitor tirabrutinib

Summary for 8FF0
Entry DOI10.2210/pdb8ff0/pdb
Related8FD9
DescriptorTyrosine-protein kinase BTK, 6-azanyl-9-[(3~{R})-1-[(~{E})-but-2-enoyl]pyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one (3 entities in total)
Functional Keywordsinhibitor, kinase, complex, covalent, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceMus musculus (house mouse)
Total number of polymer chains1
Total formula weight32278.02
Authors
Lin, D.Y.,Andreotti, A.H. (deposition date: 2022-12-07, release date: 2023-07-05, Last modification date: 2024-11-20)
Primary citationLin, D.Y.,Andreotti, A.H.
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
Plos One, 18:e0290872-e0290872, 2023
Cited by
PubMed Abstract: Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-cell survival and proliferation. Designing new inhibitors of BTK has been an important objective for advancing development of improved therapeutic agents against cancer and autoimmune disorders. Based on the success of Ibrutinib, several second-generation irreversible BTK inhibitors have been developed that exhibit fewer off-target effects. However, the binding-mode and their interaction with Btk have not been experimentally determined and evaluated at atomic resolution. Here we determined the first crystal structure of the BTK kinase domain in complex with acalabrutinib. In addition, we report a structure of the BTK/tirabrutinib complex and compare these structures with previously solved structures. The structures provide insight in the superior selectivity reported for acalabrutinb and guide future BTK inhibitor development.
PubMed: 37651403
DOI: 10.1371/journal.pone.0290872
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon